GSK plc
Leadership History
4 leaders · 2000 to present
Luke Miels is the CEO of GSK, in the role since 2026. The first chief executive was Jean-Pierre Garnier, from 2000.
| Name | Role | From | To | Years in role |
|---|---|---|---|---|
| Luke Miels | Chief Executive Officer | 2026 | Present | < 1 |
| Emma Walmsley | Former Chief Executive Officer | 2017 | 2025 | 8 |
| Andrew Witty | Former Chief Executive Officer | 2008 | 2017 | 9 |
| Jean-Pierre Garnier | Former Chief Executive Officer | 2000 | 2008 | 8 |
GSK plc is listed in London (LSE: GSK) and New York (NYSE: GSK) and is a FTSE 100 constituent. It operates in about 70 countries with 33 manufacturing sites and about 66,800 employees. The company focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Well-known products include Shingrix, Arexvy, Trelegy Ellipta, Ventolin, Nucala, Dovato and Cabenuva. The company is headquartered in London, United Kingdom.
Chief Executive Officer
2026 – Present
0 years (current)
Agreed the $10.6 billion Nuvalent acquisition in June 2026 and launched an R&D acceleration and ~$2.51 billion (£1.9 billion) cost-savings programme in July 2026.
Joined GSK in 2017 as President of Global Pharmaceuticals and later served as Chief Commercial Officer before succeeding Emma Walmsley on January 1, 2026.
Former Chief Executive Officer
2017 – 2025
8 years
Led GSK from April 2017 to December 2025, buying out Pfizer's stake in the consumer joint venture, demerging Haleon in 2022 and refocusing GSK on vaccines and specialty medicines.
Walmsley modernized a sprawling, inefficient corporate giant, transforming GSK into a focused, agile biopharmaceutical enterprise. While she faced intense initial skepticism from activist investors regarding her lack of a scientific background, her strategic vision and hard-nosed portfolio rationalization ultimately fortified the company's balance sheet and provided the capital necessary to fund future drug discovery. Her tenure established the essential foundation for the company's future growth.
Former Chief Executive Officer
2008 – 2017
9 years
During his near-decade as CEO, Andrew Witty championed a deliberately diversified corporate strategy, attempting to balance the inherent risks of drug development by heavily investing in stable, lower-margin consumer healthcare products and high-volume vaccines. He orchestrated a complex asset swap with Novartis in 2015, acquiring their global vaccines business while divesting GSK's oncology portfolio - a decision that was heavily criticized at the time but bolstered the company's vaccine dominance. He also expanded the company's footprint in emerging markets, prioritizing volume growth over high-margin pricing.
Witty provided steady leadership during a period of significant macroeconomic volatility following the 2008 financial crisis. His diversification strategy insulated the company from the devastating patent cliffs that crippled many rival pharmaceutical firms during the early 2010s. Furthermore, his commitment to tiered pricing and expanding vaccine access in developing nations significantly improved the pharmaceutical industry's global reputation regarding corporate social responsibility.
Former Chief Executive Officer
2000 – 2008
8 years
As the inaugural CEO of the newly formed GlaxoSmithKline, Jean-Pierre Garnier was tasked with the challenge of integrating two distinct corporate cultures following the historic merger of Glaxo Wellcome and SmithKline Beecham in 2000. He focused heavily on extracting promised operational synergies and streamlining the combined global manufacturing network. He also authorized aggressive, large-scale clinical trials that ultimately led to the successful commercialization of several major blockbuster drugs, including the asthma medication Advair.
Garnier executed one of the largest corporate mergers in pharmaceutical history, effectively creating the modern GSK conglomerate. His leadership established the global scale required to compete in the early 21st-century pharmaceutical market, building a strong sales and marketing infrastructure that dominated the industry for a decade. His efforts during the early 2000s cemented GSK's position as a global pharmaceutical leader, paving the way for future geographic expansion and securing the financial stability needed for sustained drug discovery programs.
GSK's largest near-term challenge is the loss of exclusivity for dolutegravir, the backbone of its HIV franchise, between 2028 and 2030; management says operating margin should be stable to improving through that period. In vaccines, narrower US recommendations sharply reduced Arexvy demand in 2024 and 2025, and Shingrix growth now depends on markets outside the US. General Medicines sales fell 9% in Q2 2026 as Trelegy faces US pricing pressure. R&D setbacks also carry costs: in Q2 2026 GSK stopped developing camlipixant for refractory chronic cough after the CALM-1/2 phase III results and booked about $1.72 billion (£1.3 billion) of impairments, which cut reported operating profit by 75% in the quarter. US drug-pricing policy and tariffs remain an ongoing risk.
Key modern CEOs of GSK include Sir Richard Sykes (who oversaw the 2000 GlaxoWellcome-SmithKline Beecham merger), Jean-Pierre Garnier (2000-2008), Sir Andrew Witty (2008-2017), and Dame Emma Walmsley (2017-present).
Dame Emma Walmsley transformed GSK by overhauling R&D leadership (appointing Dr. Hal Barron and Dr. Tony Wood), executing the historic $13 billion buyout of Novartis's consumer stake, completing the landmark 2022 demerger of Haleon, launching blockbusters Shingrix and Arexvy, and reshaping GSK into a focused biopharma innovator.
Prior to becoming CEO, Dame Emma Walmsley spent 17 years at L'Oréal in global marketing and management in the UK, Europe, and China, joining GSK in 2010 to lead Consumer Healthcare before demonstrating exceptional operational execution that led to her appointment as CEO in 2017.
Sir Andrew Witty championed global vaccine access, launched the landmark three-part multi-billion-dollar asset swap with Novartis in 2015 (acquiring Novartis vaccines while divesting GSK oncology assets), and established industry-leading transparency in clinical trial data sharing.
Recruited by Emma Walmsley from Silicon Valley (Genentech/Calico), Dr. Hal Barron and successor Dr. Tony Wood pivoted GSK's R&D strategy toward the immune system, human genetics, and advanced functional genomics, quadrupling the number of specialty medicines and vaccines in late-stage Phase 3 development.
GSK's Board of Directors aligns executive compensation with long-term shareholder value creation through performance share plans tied to pipeline clinical progression milestones, revenue growth, adjusted operating profit margin expansion, and relative total shareholder return (TSR).
Dame Emma Walmsley successfully defended GSK's strategic roadmap against activist hedge fund Elliott Management by delivering the precise execution of the Haleon spin-off on schedule, demonstrating clinical breakthroughs with Arexvy and Jemperli, and restoring double-digit sales and profit growth.
Dame Emma Walmsley's vision is to achieve over $50.2 billion (£38 billion) in annual sales by 2031, launch 12+ major new vaccines and specialty medicines, and maintain GSK's position as the world's most innovative and socially responsible vaccine and biopharmaceutical leader.
Emma Walmsley serves as CEO. When she took over in 2017, it was highly controversial because she came from the consumer goods side of the business (L'Oréal), not science. Elliott Management (a massive activist hedge fund) aggressively tried to fire her, but she survived by successfully executing the massive Haleon spin-off.
Compare executive leadership tenures and strategic transitions
Explore GSK
Core profile pages, founders and related research hubs for this company.